Matches in SemOpenAlex for { <https://semopenalex.org/work/W2330590930> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2330590930 abstract "Background: Oral anticoagulation is mandatory in patients undergoing electrical cardioversion (ECV) for atrial fibrillation (AF) to help negate the potential stroke risk. Independent prospective data concerning safety, procedural outcome and impact on procedural waiting times using novel oral anticoagulant (NOAC) treatment in ECV is limited.Methods: Analysis of all consecutive patients undergoing electrical cardioversion (ECV) between January 2013 and March 2014 was performed. Data on baseline demographics, waiting times for cardioversion, cancellations, procedural success and complications were collected.Results: A total of 229 procedures were performed during this period; 122 were anticoagulated with a NOAC (Rivaroxaban 120, Dabigatran 2, and mean age 63±12, female 31%) and 107 with Warfarin (mean age 67±10, female 41%). The mean CHA2DS2Vasc score was 2.4±1.5 versus 2.7±1.4 respectively for NOAC vs Warfarin (p=0.22). Similar corresponding mean HAS-BLED scores were observed in both groups 1.5±0.8 and 1.6±0.7 for NOAC vs Warfarin (p=0.13). No major bleeding episodes, stroke, thromboembolic events or death occurred in either group. There were significantly less cancellations in the Rivaroxaban group, 1 patient (0.8%) due to dose omission of Rivaroxaban versus 11 patients (10.3%) in the warfarin group due to sub therapeutic INRs on the day of the procedure (p=0.004). Shorter mean procedural waiting time duration was observed in the NOAC group in comparison to warfarin group (mean±SD=67±49 versus 95±66 days, p=0.006). A trend towards greater procedural success was observed in the NOAC group 94% (115/122) compared to Warfarin, 79% (85/107 p=0.001).Conclusions: This single centre experience of cardioversion with the NOACs demonstrates that the procedure is safe and effective. Cardioversion is performed in a more timely fashion, with very few cancellations and shorter waiting time, which may impact upon a greater long-term maintenance of sinus rhythm.![Graphic][1] [1]: /embed/inline-graphic-1.gif" @default.
- W2330590930 created "2016-06-24" @default.
- W2330590930 creator A5000809283 @default.
- W2330590930 creator A5013511120 @default.
- W2330590930 creator A5030378519 @default.
- W2330590930 creator A5039500853 @default.
- W2330590930 creator A5060974098 @default.
- W2330590930 creator A5061582733 @default.
- W2330590930 creator A5064866815 @default.
- W2330590930 creator A5069467054 @default.
- W2330590930 creator A5076007745 @default.
- W2330590930 creator A5087853303 @default.
- W2330590930 date "2014-10-01" @default.
- W2330590930 modified "2023-09-27" @default.
- W2330590930 title "41 * Electrical cardioversion of atrial fibrillation with the novel oral anticoagulants: a single centre UK-based registry experience" @default.
- W2330590930 doi "https://doi.org/10.1093/europace/euu239.11" @default.
- W2330590930 hasPublicationYear "2014" @default.
- W2330590930 type Work @default.
- W2330590930 sameAs 2330590930 @default.
- W2330590930 citedByCount "0" @default.
- W2330590930 crossrefType "journal-article" @default.
- W2330590930 hasAuthorship W2330590930A5000809283 @default.
- W2330590930 hasAuthorship W2330590930A5013511120 @default.
- W2330590930 hasAuthorship W2330590930A5030378519 @default.
- W2330590930 hasAuthorship W2330590930A5039500853 @default.
- W2330590930 hasAuthorship W2330590930A5060974098 @default.
- W2330590930 hasAuthorship W2330590930A5061582733 @default.
- W2330590930 hasAuthorship W2330590930A5064866815 @default.
- W2330590930 hasAuthorship W2330590930A5069467054 @default.
- W2330590930 hasAuthorship W2330590930A5076007745 @default.
- W2330590930 hasAuthorship W2330590930A5087853303 @default.
- W2330590930 hasBestOaLocation W23305909301 @default.
- W2330590930 hasConcept C126322002 @default.
- W2330590930 hasConcept C127413603 @default.
- W2330590930 hasConcept C164705383 @default.
- W2330590930 hasConcept C2776301958 @default.
- W2330590930 hasConcept C2777289489 @default.
- W2330590930 hasConcept C2778661090 @default.
- W2330590930 hasConcept C2778810321 @default.
- W2330590930 hasConcept C2779161974 @default.
- W2330590930 hasConcept C2780645631 @default.
- W2330590930 hasConcept C42219234 @default.
- W2330590930 hasConcept C71924100 @default.
- W2330590930 hasConcept C78519656 @default.
- W2330590930 hasConceptScore W2330590930C126322002 @default.
- W2330590930 hasConceptScore W2330590930C127413603 @default.
- W2330590930 hasConceptScore W2330590930C164705383 @default.
- W2330590930 hasConceptScore W2330590930C2776301958 @default.
- W2330590930 hasConceptScore W2330590930C2777289489 @default.
- W2330590930 hasConceptScore W2330590930C2778661090 @default.
- W2330590930 hasConceptScore W2330590930C2778810321 @default.
- W2330590930 hasConceptScore W2330590930C2779161974 @default.
- W2330590930 hasConceptScore W2330590930C2780645631 @default.
- W2330590930 hasConceptScore W2330590930C42219234 @default.
- W2330590930 hasConceptScore W2330590930C71924100 @default.
- W2330590930 hasConceptScore W2330590930C78519656 @default.
- W2330590930 hasLocation W23305909301 @default.
- W2330590930 hasOpenAccess W2330590930 @default.
- W2330590930 hasPrimaryLocation W23305909301 @default.
- W2330590930 hasRelatedWork W2037830341 @default.
- W2330590930 hasRelatedWork W2095661544 @default.
- W2330590930 hasRelatedWork W2101467763 @default.
- W2330590930 hasRelatedWork W2185949107 @default.
- W2330590930 hasRelatedWork W2222437011 @default.
- W2330590930 hasRelatedWork W2291198182 @default.
- W2330590930 hasRelatedWork W2415101536 @default.
- W2330590930 hasRelatedWork W2504381309 @default.
- W2330590930 hasRelatedWork W2517024478 @default.
- W2330590930 hasRelatedWork W2555798720 @default.
- W2330590930 hasRelatedWork W2582711066 @default.
- W2330590930 hasRelatedWork W2695460838 @default.
- W2330590930 hasRelatedWork W2734532792 @default.
- W2330590930 hasRelatedWork W2734548116 @default.
- W2330590930 hasRelatedWork W2791650917 @default.
- W2330590930 hasRelatedWork W2925118546 @default.
- W2330590930 hasRelatedWork W3009257459 @default.
- W2330590930 hasRelatedWork W3011311124 @default.
- W2330590930 hasRelatedWork W3020243675 @default.
- W2330590930 hasRelatedWork W3029763821 @default.
- W2330590930 isParatext "false" @default.
- W2330590930 isRetracted "false" @default.
- W2330590930 magId "2330590930" @default.
- W2330590930 workType "article" @default.
!["Background: Oral anticoagulation is mandatory in patients undergoing electrical cardioversion (ECV) for atrial fibrillation (AF) to help negate the potential stroke risk. Independent prospective data concerning safety, procedural outcome and impact on procedural waiting times using novel oral anticoagulant (NOAC) treatment in ECV is limited.Methods: Analysis of all consecutive patients undergoing electrical cardioversion (ECV) between January 2013 and March 2014 was performed. Data on baseline demographics, waiting times for cardioversion, cancellations, procedural success and complications were collected.Results: A total of 229 procedures were performed during this period; 122 were anticoagulated with a NOAC (Rivaroxaban 120, Dabigatran 2, and mean age 63±12, female 31%) and 107 with Warfarin (mean age 67±10, female 41%). The mean CHA2DS2Vasc score was 2.4±1.5 versus 2.7±1.4 respectively for NOAC vs Warfarin (p=0.22). Similar corresponding mean HAS-BLED scores were observed in both groups 1.5±0.8 and 1.6±0.7 for NOAC vs Warfarin (p=0.13). No major bleeding episodes, stroke, thromboembolic events or death occurred in either group. There were significantly less cancellations in the Rivaroxaban group, 1 patient (0.8%) due to dose omission of Rivaroxaban versus 11 patients (10.3%) in the warfarin group due to sub therapeutic INRs on the day of the procedure (p=0.004). Shorter mean procedural waiting time duration was observed in the NOAC group in comparison to warfarin group (mean±SD=67±49 versus 95±66 days, p=0.006). A trend towards greater procedural success was observed in the NOAC group 94% (115/122) compared to Warfarin, 79% (85/107 p=0.001).Conclusions: This single centre experience of cardioversion with the NOACs demonstrates that the procedure is safe and effective. Cardioversion is performed in a more timely fashion, with very few cancellations and shorter waiting time, which may impact upon a greater long-term maintenance of sinus rhythm.![Graphic][1] [1]: /embed/inline-graphic-1.gif"](?object=%22Background%3A%20Oral%20anticoagulation%20is%20mandatory%20in%20patients%20undergoing%20electrical%20cardioversion%20(ECV)%20for%20atrial%20fibrillation%20(AF)%20to%20help%20negate%20the%20potential%20stroke%20risk.%20Independent%20prospective%20data%20concerning%20safety%2C%20procedural%20outcome%20and%20impact%20on%20procedural%20waiting%20times%20using%20novel%20oral%20anticoagulant%20(NOAC)%20treatment%20in%20ECV%20is%20limited.Methods%3A%20Analysis%20of%20all%20consecutive%20patients%20undergoing%20electrical%20cardioversion%20(ECV)%20between%20January%202013%20and%20March%202014%20was%20performed.%20Data%20on%20baseline%20demographics%2C%20waiting%20times%20for%20cardioversion%2C%20cancellations%2C%20procedural%20success%20and%20complications%20were%20collected.Results%3A%20A%20total%20of%20229%20procedures%20were%20performed%20during%20this%20period%3B%20122%20were%20anticoagulated%20with%20a%20NOAC%20(Rivaroxaban%20120%2C%20Dabigatran%202%2C%20and%20mean%20age%2063%C2%B112%2C%20female%2031%25)%20and%20107%20with%20Warfarin%20(mean%20age%2067%C2%B110%2C%20female%2041%25).%20The%20mean%20CHA2DS2Vasc%20score%20was%202.4%C2%B11.5%20versus%202.7%C2%B11.4%20respectively%20for%20NOAC%20vs%20Warfarin%20(p%3D0.22).%20Similar%20corresponding%20mean%20HAS-BLED%20scores%20were%20observed%20in%20both%20groups%201.5%C2%B10.8%20and%201.6%C2%B10.7%20for%20NOAC%20vs%20Warfarin%20(p%3D0.13).%20No%20major%20bleeding%20episodes%2C%20stroke%2C%20thromboembolic%20events%20or%20death%20occurred%20in%20either%20group.%20There%20were%20significantly%20less%20cancellations%20in%20the%20Rivaroxaban%20group%2C%201%20patient%20(0.8%25)%20due%20to%20dose%20omission%20of%20Rivaroxaban%20versus%2011%20patients%20(10.3%25)%20in%20the%20warfarin%20group%20due%20to%20sub%20therapeutic%20INRs%20on%20the%20day%20of%20the%20procedure%20(p%3D0.004).%20Shorter%20mean%20procedural%20waiting%20time%20duration%20was%20observed%20in%20the%20NOAC%20group%20in%20comparison%20to%20warfarin%20group%20(mean%C2%B1SD%3D67%C2%B149%20versus%2095%C2%B166%20days%2C%20p%3D0.006).%20A%20trend%20towards%20greater%20procedural%20success%20was%20observed%20in%20the%20NOAC%20group%2094%25%20(115%2F122)%20compared%20to%20Warfarin%2C%2079%25%20(85%2F107%20p%3D0.001).Conclusions%3A%20This%20single%20centre%20experience%20of%20cardioversion%20with%20the%20NOACs%20demonstrates%20that%20the%20procedure%20is%20safe%20and%20effective.%20Cardioversion%20is%20performed%20in%20a%20more%20timely%20fashion%2C%20with%20very%20few%20cancellations%20and%20shorter%20waiting%20time%2C%20which%20may%20impact%20upon%20a%20greater%20long-term%20maintenance%20of%20sinus%20rhythm.!%5BGraphic%5D%5B1%5D%20%5B1%5D%3A%20%2Fembed%2Finline-graphic-1.gif%22){kind=link}